Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest Update

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 7,480,000 shares, a growth of 29.2% from the December 31st total of 5,790,000 shares. Based on an average daily trading volume, of 1,410,000 shares, the days-to-cover ratio is presently 5.3 days.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 9th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Aurinia Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $10.00.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $8.43, for a total transaction of $38,415.51. Following the completion of the transaction, the director now directly owns 13,356 shares of the company’s stock, valued at approximately $112,591.08. The trade was a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Blue Trust Inc. increased its holdings in shares of Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 6,174 shares during the period. CWM LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 247.7% during the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock worth $84,000 after buying an additional 8,180 shares during the period. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at about $84,000. FMR LLC increased its position in Aurinia Pharmaceuticals by 44.8% in the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after buying an additional 3,919 shares during the period. Finally, Union Bancaire Privee UBP SA acquired a new position in Aurinia Pharmaceuticals during the 4th quarter valued at $108,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

Shares of Aurinia Pharmaceuticals stock opened at $7.76 on Monday. The firm’s 50-day simple moving average is $8.68 and its 200-day simple moving average is $7.49. Aurinia Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $10.67. The firm has a market cap of $1.11 billion, a PE ratio of -51.60 and a beta of 1.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.